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Abstract
Objectives: Using the findings of the Global Burden of Disease Study (GBD), we report the burden of primary
headache disorders in the Eastern Mediterranean Region (EMR) from 1990 to 2016.
Methods: We modelled headache disorders using DisMod-MR 2.1 Bayesian meta-regression tool to ensure consistency
between prevalence, incidence, and remission. Years lived with disability (YLDs) were calculated by multiplying
prevalence and disability weight (DW) of migraine and tension-type headache (TTH). We assumed primary headache
disorders as non-fatal, so their YLD is equal to disability-adjusted life years (DALYs).
Results: Migraine and TTH were the second and twentieth leading causes of YLDs in EMR. Between 1990 and 2016,
the absolute YLD numbers of migraine and TTH increased from 2.3 million (95% uncertainty interval (UI): 1.5–3.2) to
4.7 million (95%UI: 3–6.5) and from 383 thousand (95%UI: 240–562) to 816 thousand (95%UI: 516–1221), respectively.
During the same period, age-standardised YLD rates of migraine and TTH in EMR increased by 0.7% and 2.5%,
respectively, in comparison to a small decrease in the global rates (0.2% decrease in migraine and TTH). The bulk of
burden due to headache occurred in the 30–49 year age group, with a peak at ages 35–44 years. The age-standardised
YLD rates of both headache disorders were higher in women with female to male ratio of 1.69 for migraine and 1.38
for TTH. All countries of the EMR except for Somalia and Djibouti had higher age-standardised YLD rates for migraine
and TTH in compare to the global rates. Libya and Saudi Arabia had the highest increase in age-standardised YLD rates
of migraine and TTH, respectively.
Conclusion: The findings of this study show that primary headache disorders are a major and a growing cause of
disability in EMR. Since 1990, burden of primary headache disorders has constantly been higher in EMR compared to
rest of the world, which indicates that health systems in EMR must focus further on developing and implementing
preventive and management strategies to control headache.
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Disability-adjusted life years (DALYs), Global burden of disease study (GBD), Eastern Mediterranean region (EMR)
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Introduction
Headache, with the global prevalence of 47%, is one of
the most common neurological disorders [1] Headache
can be a secondary symptom of an underlying condi-
tions (e.g. intracranial neoplasms, epileptic seizures, and
intracranial infections); however, in most cases it is a
primary and non-fatal disorder [2, 3]. Primary headaches
such as migraine, tension-type headache (TTH), and
cluster headache, although non-fatal, cause substantial
disability and economic cost [4–7].
Global Burden of Diseases, Injuries and Risk Factors
study (GBD) is a comprehensive worldwide epidemio-
logic study being performed since 1990 [8, 9]. Estimation
of years lived with disability (YLDs) and prevalence of
diseases were among the main objectives of GBD [4]. In
GBD 2000, for the first time, migraine was included as
the only headache subtype. Since then, TTH was added
to the GBD study, and some of the limitations in the
previous estimates were addressed by using more com-
prehensive and reliable epidemiologic data based on
population-based surveys from countries without previ-
ous available data [4]. GBD 2016, provided more accur-
ate estimations of prevalence and burden of headache by
countries, regions, and super regions [4].
According to GBD 2016, prevalence of headache disor-
ders was variable across different geographic regions.
For example, migraine was less frequent in African and
Western Pacific WHO regions and TTH was less frequent
in African region. However, the overall global all-age
prevalence of migraine and TTH were estimated to be
14.1% (95% uncertainty interval [UI] 13.5–14.8%), and
25.6% (95% UI 23.1–28.4) respectively in 2016. Although
prevalence of headache is an important epidemiologic
measure, the burden of disability related to headache, as
measured by YLD, is more informative for health policy
making. Globally, migraine, with 45,121,909 YLDs (95%
UI 29,045,835-62,826,904), and TTH, with 7,195,122
YLDs (95% UI 4,614,628-10,499,903), were the second
and 28 leading causes of disability.
Despite the considerable burden, headache disorders
are still underestimated and underdiagnosed [1, 10]. A
study has estimated that the headache diagnosis rate is
under 40% [11], which leads to a high undertreated rate.
Effective treatment for most primary headache cases can
be provided by primary health service and with low cost
[11]; therefore, improvement of the diagnosis and treat-
ment rate will substantially reduce the burden of
headache.
GBD 2016 emphasized that primary headache disor-
ders are an important health priority. Estimating the
burden of headache is the first step to implement further
measures to reduce its burden such as educating health
care providers, developing primary care management,
and allocating resources. In this study, we reported the
prevalence and burden of primary headache disorders
(including migraine and TTH) in Eastern Mediterranean
Region (EMR) countries from 1990 to 2016 using data
and methods of the Global Burden of Diseases, Injuries,
and Risk Factors Study 2016.
Methods
Overview
The Global Burden of Diseases, Injuries, and Risk
Factors Study 2016 (GBD 2016) is a standardised ana-
lytical method that used all eligible sources to esti-
mate the epidemiological data, including prevalence,
mortality, years of life lost (YLL), YLDs, and
disability-adjusted life years (DALYs), for 328 causes
by sex, age, and location from 1990 to 2016. It esti-
mates all parameters for 195 countries and territories,
nested in twenty-one regions and seven super-regions.
Details of the methodology of GBD studies and the
main changes applied in GBD 2016 has been ex-
plained in another article [4].
Locations, causes, and parameters
The World Health Organization (WHO) EMR, home
to approximately 600 million people [12], contains
22 countries: Afghanistan, Bahrain, Djibouti, Egypt,
Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco,
Oman, Pakistan, Palestine, Qatar, Saudi Arabia,
Somalia, Sudan, Syria, Tunisia, United Arab Emirates, and
Yemen. In this article all epidemiologic parameters have
been reported for the whole EMR region and all countries
separately.
From the category of neurological disorders, we in-
cluded migraine and tension-type headache (TTH) - the
two types of primary headache disorders which were
covered in GBD 2016. In the previous GBD iteration
(GBD 2015), in addition to migraine and TTH, medica-
tion overuse headache (MOH) was also included as a
separate disorder. In the present iteration, MOH has
been removed as an independent cause, and the YLDs of
MOH has been calculated as a sequel of migraine and
TTH. Based on the previous studies, 73 % of total MOH
YLDs were classified as a sequel of migraine (MOH due
to migraine) and the rest of them were classified as a se-
quel of TTH (MOH due to TTH) [13–15]. Secondary
headache disorders were not included in this study.
In this article, we presented numbers and rates of
prevalence and YLDs of migraine and TTH in 2016 and
the changes from 1990 to 2016 for all EMR countries.
We assumed that primary headache disorders do not
lead to mortality and, therefore, disability adjusted
life-years (DALYs) of migraine and TTH are equal to
their YLDs.
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Data sources
In GBD 2016, systematic review for migraine, TTH,
and MOH were updated as part of the GBD standard
methodology. Details on the data sources have been
described elsewhere [16]. From the EMR, data sources
from Iran [17–19], Pakistan [20], Tunisia [21], and
UAE [22] for migraine, and data sources from Iran
[17, 19, 23], Pakistan [20], and Qatar [24] for TTH
were used in GBD 2016; however, data inputs from
all over the world were used to model the burden of
migraine and TTH in EMR countries.
Modeling
In order to make data more consistent and suitable
for modelling, age-sex splitting was applied to the
sources that had reported data by age or sex but not
by both age and sex.
Non-fatal modelling, using DisMod-MR 2.1, were
performed to estimate prevalence and incidence of mi-
graine, TTH, and MOH. DisMod-MR 2.1 is a Bayesian
meta-regression method that estimates non-fatal out-
comes using sparse and heterogeneous epidemiological
data. It also pools data from different sources and ad-
justs them for variations in study methods across
sources and enforces consistency between different epi-
demiological parameters. Binary study-level covariates
were used in modelling to minimize residual errors of
the estimated prevalence and YLDs. Using the
mixed-effects nonlinear regression on all the available
data at the global level, super-region Bayesian priors
were generated; likewise, the super-region regression
model was then used to generate region Bayesian priors,
and so on down the cascade. Bayesian priors of the EMR
countries were generated by using three different
super-region models: Eastern Sub-Saharan Africa model
for Djibouti and Somalia, South Asia model for Pakistan,
and North Africa and Middle East model for the rest of
EMR countries. For GBD 2016, the same disability
weights (DW) as in GBD 2015 were used. Table 1 dis-
plays ICD 10 and ICD 9 codes, sequelae, description,
and DW of primary headache disorders.
YLD computation
YLDs were calculated by multiplying prevalence and
DW for each sequel, and then YLDs were adjusted
for occurrence of simultaneous comorbidities. Co-
morbidity with additional disorders in a patient with
primary headache was estimated by calculating the
independent probability of having simultaneous
sequelae.
Uncertainty interval and age-standardised values
We repeated calculation of comorbidity-adjusted
YLDs 1000 times and generated a distribution with
the 1000 samples. The 25th and 975th values of the
1000 draws determined the upper and lower bounds
of the 95% UI. Age-standardised prevalence rate and
age-standardised YLD rates were calculated using the
GBD reference population [25].
Socio-demographic Index (SDI) and expected YLD rates
on the basis of SDI
SDI was used to provide a comparable metric for
overall sociodemographic development. SDI, expressed
on a scale of 0 to 1, is a summary measure that iden-
tifies where GBD locations sit on the spectrum of
socioeconomic development [26]. SDI was calculated
based on the geometric mean of lag-distributed in-
come (LDI), average years of schooling among popu-
lations aged 15 years or older, and total fertility rate
(TFR). Five SDI quintiles, high, high-middle, middle,
low-middle, and low, were selected based on SDI
values. More details regarding the calculation of SDI
are provided in previous GBD publications [4, 27].
Expected YLD rates at each level SDI were gener-
ated by a Gaussian regression model [4, 28]. Expected
YLD rates on the basis of SDI was compared to the
observed values to investigate the performance of
countries on the basis of what would be expected on
the basis of their overall development.
Results
Prevalence
Estimated all-age prevalence of TTH and migraine in
EMR for 2016 were 29.7% (95% UI 26.8–33) and
15.9% (95% UI 15.2–16.8), respectively. Between
1990 and 2016, the number of individuals with mi-
graine in EMR increased from 53 million (95% UI
50–55 million) to 105 million (95% UI 100–110
million), and the number of individuals with TTH
increased from 107 million (95% UI 96–119 million)
to 195 million (95% UI 176–217 million). From 1990
to 2016, age-standardised prevalence of migraine and
TTH remained generally unchanged both in the
EMR and globally, with a constant higher rate in the
EMR (Fig. 1).
In the EMR, prevalence of headache was higher in fe-
males, with prevalence count female to male ratio of 1.7
and 1.2 for migraine and TTH, respectively. Headache
was most common in young and middle-aged adults,
with highest prevalence count in 35 to 39 year age group
for both migraine (25.9, 95% UI 23.7–28.5%) and TTH
(46, 95% UI 33.9–57.8%).
Djibouti had the lowest and Pakistan had the highest
prevalence numbers for both migraine and TTH. From
1990 to 2016, UAE had the highest increase in the num-
ber of individuals with migraine and TTH (Table 2). In
2016, Pakistan had the highest age-standardised
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prevalence rate of migraine and Afghanistan had the
highest age-standardised prevalence rate of TTH, while
Djibouti had the lowest age-standardised prevalence for
both migraine and TTH (Table 2). In Web Additional
file 1: Table S1 we reported the details of prevalence of
headache disorders in EMR countries for sex and age
groups from 1990 to 2016.
Disability
In 2016, there were an estimated 4.7 million (95% UI
3–6.6 million) YLDs for migraine and 0.8 million
(95% UI 0.5–1.2) YLDs for TTH in EMR. We ranked
the leading causes of YLDs in 1990 and 2016 at level
4 of the GBD cause hierarchy in EMR. Among the
causes with the highest YLDs, migraine had the sec-
ond position in both 1990 and 2016, and TTH rose
from the 25th to the 20th position. During the same
period, the relative contribution of migraine YLDs
and TTH YLDs to the overall YLDs in EMR in-
creased from 6.0% (95% UI 4.3–7.8) to 6.7% (95% UI
4.9–8.5) and from 1.00% (95% UI 0.75–1.30) to 1.16%
(95% UI 0.86–1.49), respectively.
YLDs from primary headache disorders were high-
est in young and middle-aged adults. The highest
proportion of YLDs due to migraine occurred be-
tween ages 30 and 49, with a peak in the 35–44 year
age group. The highest proportion of YLDs due to
TTH occurred in 30–59 year age group, with a peak
in the 35–44 year age group. Across all age groups,
YLD rates of both migraine and TTH were consider-
ably higher in females compared to males (Fig. 2). In
the EMR, female to male ratio of age-standardised
YLDs were 1.69 for migraine and 1.38 for TTH.
From 1990 to 2016, age-standardised YLD rates of
migraine and TTH remained generally unchanged.
During this period, EMR had a constantly higher
YLD rates compared to the global rates. Since 1990,
EMR had greater than expected age-standardised
YLD rates on the basis of SDI (observed to expected
YLD rates of greater than 1) (Fig. 3).
Comparing the overall all-age YLD rates of migraine
and TTH combined, Kuwait had the highest and
Djibouti had the lowest YLD rates. Across all EMR
countries, all age YLD rates for both migraine and TTH
Table 1 ICD 10 codes, ICD 9 codes, sequelae, description, and disability weight of migraine and TTH




headache due to migraine
- -
Asymptomatic migraine - -
Symptomatic medication overuse
headache due to migraine
Has daily headaches, felt as dull pain
and often lasting all day, with poor
sleep, nausea and fatigue. The person
takes medicine for the headaches,
which provides little relief but is needed
to avoid having worse symptoms.
0.223 (0.146–0.313)
Symptomatic migraine Has severe, throbbing head pain and
nausea that cause great difficulty in
daily activities and sometimes confine
the person to bed. Moving around,







headache due to tension-type
headache
- -
Asymptomatic tension-type headache - -
Symptomatic medication overuse
headache due to tension-type
headache
Has daily headaches, felt as dull pain
and often lasting all day, with poor
sleep, nausea and fatigue. The person
takes medicine for the headaches,
which provides little relief but is needed
to avoid having worse symptoms.
0.223 (0.146–0.313)
Symptomatic tension-type headache Has a moderate headache that also
affects the neck, which causes difficulty
in daily activities.
0.037 (0.022–0.057)
ICD-10 International Statistical Classification of Diseases and Related Health Problems, tenth revision, ICD-9 International Statistical Classification of Diseases and
Related Health Problems, ninth revision
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were greater in females rather than males (Fig. 4). In
Web Additional file 2: Table S2 we displayed the details
of burden of headache disorders in EMR countries for
sex and age groups from 1990 to 2016.
For migraine, YLD numbers and rates in 2016, YLD
changes between 1990 and 2016, and the ratio of ob-
served to expected YLDs on the basis of SDI in 2016
across EMR countries have been showed in Table 3. Iran,
Oman, and Saudi Arabia had the largest, and Somalia
had the smallest increase in all-age YLD rates for mi-
graine between 1990 and 2016. During the same period,
age-standardised YLD rates of migraine remained gener-
ally unchanged in EMR countries. The ratio of observed
to expected age-standardised YLD rate for migraine
ranged from 0.82 in Djibouti to 1.31 in Palestine. Only
three countries -Djibouti, Somalia, and UAE- had lower
observed than expected age-standardised YLD rate for
migraine, two of them within Eastern Sub-Saharan Africa
(SSA). The five locations with the highest age-standardised
YLD rates relative to the rates expected on the basis of SDI
were Palestine, Iraq, Yemen, Sudan, and Afghanistan.
High-income countries in EMR generally had ratios of ob-
served to expected YLD rates close to one.
YLD numbers and rates of TTH in 2016, their changes
from 1990 to 2016, and the ratio of observed to expected
YLD rates on the basis of SDI in 2016 for EMR coun-
tries have been showed in Table 4. Iran, Oman, and
Saudi Arabia had the highest increase in all-age YLD
rate for TTH, while Somalia showed a slight decrease
in all-age YLD rate for TTH. Similar to migraine,
age-standardised YLD rates of TTH showed an overall
consistency between 1990 and 2016 in EMR countries.
Observed to expected age-standardised YLD rate ratio
for TTH ranged from 0.85 in Djibouti to 1.42 in Iran.
Djibouti and Somalia (both located in Eastern SSA and
among low-income countries) were the only two coun-
tries with observed to expected age-standardised YLD
rate lower than one. Locations with the highest level of
age-standardised YLDs relative to the level expected on
the basis of SDI were Iran, Palestine, Afghanistan, Iraq,
Sudan, Yemen.
Discussion
This is the first study to investigate the prevalence and
burden of headache in EMR. Our study provides a com-
prehensive assessment of the values and trends of preva-
lence and burden of primary headache disorders in EMR
countries and their trends from 1990 to 2016. Our find-
ings are of great value to health professionals and their
efforts to reduce the burden of headache in the region.
Indeed, our results could be used for planning and
implementing programs to address this burden.
From 1990 to 2016, despite the overall consistent
age-standardised YLD rates of headache, the all-age YLD
rates and the total number of people suffering from
headache has substantially increased. This finding is
consistent with the global growing burden of
non-communicable diseases [4]. Consistent
Fig. 1 Change in age-standardised prevalence rates from 1990 to 2016. Abbreviations: TTH, tension-type headache; EMR, Eastern
Mediterranean Region
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age-standardised YLD rates along with the increase of
number of people affected by headache indicates the
role of population growth and ageing as the main fac-
tors of the increase in the burden of headache
disorders.
Burden of headache was generally higher in the EMR
countries compared to global average. Risk factors for
progression of episodic migraine to chronic migraine
can explain a part of the higher burden of headache in
the EMR. Studies suggest that primary chronic migraine
is rare, and chronic migraine usually progresses from
episodic migraine. Gradual increase in frequency of epi-
sodic migraine attacks progresses to chronic migraine
with an annual rate of 2.5% [29, 30]. The most important
risk factors for progression of episodic migraine to
chronic migraine are medication overuse for migraine
attacks, obesity, depression, anxiety, and stressful life
events [31, 32]. The higher rates of depression and anx-
iety in the EMR compared to the rest of the world can
play a role in the higher burden of migraine in this re-
gion. In 2013, mental disorders contributed to 19.0% of
non-fatal burden in the EMR, in comparison to
17.4% of global non-fatal burden [33]. Stressful life
events can be another contributor of the higher bur-
den of migraine in the EMR. For example, countries
with ongoing or recent conflicts such as Palestine,
Iraq, Yemen, Sudan, and Afghanistan had the highest
observed than expected age-standardised YLD rates
of migraine on the basis of their SDI. However,
given the limited data sources from the EMR
countries, the role of risk factors of chronic migraine
in higher burden of headache in the EMR should be
interpreted cautiously.
The EMR had greater than expected
age-standardised YLD rates on the basis of SDI for
headache, and the gap between observed and ex-
pected rates remained generally unchanged from 1990
to 2016. In contrast, worldwide observed
age-standardised YLD rates were lower than the ex-
pected values during the same period. Constant high
ratio of age-standardised YLD rates relative to that
expected in the EMR suggests poor performance of
health service in terms of headache outcomes relative
to the development status, reflecting a need for add-
itional attention to the reasons of this underperform-
ance and policy implications for health reforms in
EMR countries.
YLD rate of migraine and TTH were highest be-
tween ages 25 and 54 years, which is consistent with
the literature [34]. However, the burden of headache
is still considerable in 5–24 and 55–74 year old age
groups.
Estimated all-age prevalence rates for migraine and
TTH in the EMR were higher compared with the
global rates. A review on epidemiological studies be-
tween 1988 and 2005 estimated that the global
prevalence of migraine and TTH were 10% and 38%
respectively [1]. However, studies have shown a wide
variation in the prevalence of primary headache dis-
orders, partly because of the differences in
Fig. 2 YLD rates of migraine and TTH by age in EMR for females (a) and males (b) in 2016. Abbreviations: TTH, tension-type headache; EMR,
Eastern Mediterranean Region
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methodology. Particularly for TTH, case definition
has been a challenge; for example, variation in fre-
quency and duration of TTH and its overlap with
migraine may have led to differences in prevalence
[35]. Disparity in prevalence rates, reported by stud-
ies with different methodology, made them
non-comparable over time and across geographic
areas. GBD, however, is a systematic approach that
has the important advantage of providing comparable
prevalence and burden over time and by geography.
Our findings have important health service impli-
cations. The significant and increasing non-fatal
burden of headache inform policy makers and health
care providers of EMR countries that primary head-
ache should be a health care priority, and interven-
tion strategies focusing on improvement of diagnosis
and treatment of headache must be implemented.
Primary headache is one of the leading causes of dis-
ability; meanwhile, effective and low-cost treatments
are available for most patients with primary head-
ache (including patients with migraine and TTH). In
most cases, patients with primary headaches can be
diagnosed and treated by the primary health-care
physicians. Moreover, high prevalence of primary
A
B
Fig. 3 Trends of observed age-standardised YLD rates and expected age-standardised YLD rates on the basis of SDI for migraine (a) and TTH (b)
in the EMR and globally. Abbreviations: TTH, tension-type headache; EMR, Eastern Mediterranean Region
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headaches across a wide range of ages necessitates
interventional strategies that, in the first place, target
the primary health service. Better education of
health-care professionals, especially those who work
in primary health-care services, is the most essential
part of interventional strategies to reduce the burden
of headache. Health-care professionals should be ed-
ucated to properly diagnose and treat patients with
primary headache disorders. Providing diagnostic and
treatment guidelines, especially for non-expert
healthcare providers is also a practical method espe-
cially for the low-income countries [11].
The implication of these findings is that invest-
ment in interventional strategies for diagnosis and
treatment of headache will lead to a considerable re-
duction in the healthcare costs and the burden of
headache. Our study calls for more population-based
surveys investigating the prevalence and severity of
primary headache disorders in EMR countries.
Population-based and disease-specific surveys
providing better data coverage on headache epidemi-
ology in EMR are needed for more accurate esti-
mates of primary headache burden in the region.
Quality of life and financial impacts are important
contributors of the burden. For example, with a mean
per-person annual cost of €1222, the annual total cost
of migraine has been estimated to be €111 billion in
Europe in 2009 [36]. Another study estimated the
mean per-person annual cost of episodic and chronic
migraine at $2649 and $8243 in the US in 2013 [37].
Furthermore, studies from Sweden [38], then US [39],
and the UK [40] have reported that migraine has a
considerable negative effect on family quality of life.
In this study, although we estimated the most import-
ant contributors of the headache’s burden, we did not
capture its costs and quality of life.
This study has some limitations. The main concern
is the lack of adequate data and poor quality of the
available data from the EMR. Since accessible data
sources for prevalence of migraine and TTH in EMR
Fig. 4 All-age YLD rates for migraine and TTH in the Eastern Mediterranean countries, by country and sex. Abbreviations: YLD, years lived with
disability; TTH, tension-type headache; UAE, United Arab Emirate
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are scarce, we were able to use data from only few
of the EMR countries. In comparison to GBD 2013,
with prevalence data from only one EMR country
(Iran), GBD 2016 is an obvious improvement; how-
ever, there is still no reliable data from most of the
EMR countries. Unfortunately, the region is facing
several health challenges which divert attention from
headaches in the mind of many health professionals.
However, we hope that our study will increase the at-
tention to this large burden and lead to improved
data. Second, although we estimated prevalence and
YLDs of the primary headache disorders with
considerable burden (including migraine, TTH, and
MOH - as a sequel of the first two syndromes), we
could not include all primary headache disorders clas-
sified in ICD-10 classification [41]. Cluster headache,
for example, was the most important headache syn-
drome that we did not capture in this GBD iteration.
Conclusion
Findings from this study show that primary head-
ache disorders are a large cause of disability in the
EMR. Despite generally unchanged age-standardised
YLDs, YLD numbers increased substantially
Table 3 YLD count, All-age YLD rates, and Age-standardised rates in 2016, and percentage change of YLD count, All-age YLD rates,
and Age-standardised rates between 1990 and 2016 for migraine in EMR countries












Somalia 42078 (27076-59527) 71.1 (63.6 to 78.5) 477 (307-666) 0 (-3.8 to 4) 0.82 1.79 0.27
Afghanistan 208981 (134134-294141) 199.7 (187 to 212.8) 737 (479-1027) 0.5 (-3.4 to 4.4) 1.27 1.72 0.28
Djibouti 4119 (2626-5753) 78 (70.1 to 85.6) 473 (304-657) -0.9 (-4.5 to 2.7) 0.82 1.8 0.42
Yemen 180267 (115752-254144) 175.9 (164.8 to 187.2) 749 (486-1044) 0.2 (-3.2 to 3.7) 1.29 1.71 0.45
Middle-income Countries
Palestine 31910 (20345-44967) 159.2 (149.3 to 169.6) 760 (487-1061) 0.2 (-3.1 to 3.5) 1.31 1.72 0.45
Iraq 245414 (157277-342808) 135.5 (125.8 to 146) 754 (488-1052) 0.6 (-2.9 to 4.3) 1.29 1.73 0.47
Sudan 273586 (176305-381268) 124.5 (115.4 to 133) 760 (491-1059) 1.2 (-2.2 to 4.7) 1.28 1.72 0.52
Pakistan 1299007 (829027-1845495) 97.9 (91.4 to 105.3) 730 (468-1034) -0.6 (-3.6 to 2.5) 1.23 1.62 0.52
Morocco 271235 (174130-382333) 64.1 (56.6 to 72.5) 770 (496-1084) 1.3 (-2.3 to 5.1) 1.25 1.71 0.62
Syria 130923 (84689-183571) 75.3 (67.9 to 84) 767 (496-1071) 1.4 (-2 to 5.3) 1.23 1.72 0.64
Egypt 674197 (433516-936625) 84.5 (77.6 to 92.4) 766 (494-1064) 0.9 (-2.5 to 4.9) 1.21 1.71 0.65
Jordan 55454 (35403-77551) 180 (166.9 to 193.4) 762 (492-1066) 1.9 (-1.7 to 5.5) 1.18 1.71 0.69
Tunisia 90158 (58559-124945) 64.4 (58 to 72.2) 755 (492-1048) 1.8 (-1.5 to 5.4) 1.17 1.73 0.70
Iran 653679 (425780-905798) 93.9 (85.8 to 102.5) 758 (497-1054) 2.3 (-1 to 5.7) 1.13 1.74 0.77
Libya 49500 (32133-69680) 75.6 (67.5 to 84.6) 771 (500-1085) 3.3 (-0.3 to 7.3) 1.13 1.71 0.81
Lebanon 47836 (30941-66597) 150.2 (140.8 to 160) 767 (496-1073) 0.5 (-2.9 to 3.9) 1.13 1.71 0.81
High-income Countries
Oman 36619 (23376-50763) 234.9 (217.5 to 254.6) 700 (454-972) -3.5 (-7.4 to 0.9) 1.07 1.72 0.72
Bahrain 11300 (7222-15841) 219.7 (205.8 to 234.5) 716 (463-1004) -0.6 (-4.2 to 3.2) 1.08 1.7 0.74
United Arab Emirates 76336 (49496-107622) 513.9 (486.9 to 545.1) 659 (430-915) -1.2 (-4.8 to 2.8) 0.98 1.73 0.77
Qatar 18937 (12171-26563) 445.1 (422.6 to 470) 678 (441-948) -0.8 (-4.3 to 3.1) 1 1.71 0.79
Saudi Arabia 267107 (172575-373293) 146.1 (139.5 to 154.2) 794 (517-1110) 2.8 (0.8 to 4.9) 1.17 1.69 0.80
Kuwait 33859 (21841-48110) 126.6 (116.6 to 136.9) 745 (486-1050) 0.6 (-3.1 to 4.3) 1.09 1.71 0.83
EMR and global
EMR 4702503 (3025930-6551569) 106.7a 746 (482-1039) 0.7a 1.21 1.69 N/A
Global 45121909 (29045835-62826904) 51.3 (49.7 to 52.8) 599 (386-833) -0.2 (-0.8 to 0.4) 0.93 1.84 0.70
YLD years lived with disability, EMR eastern Mediterranean region
a Uncertainty interval is not available
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between 1990 and 2016 in the EMR-mostly due to
the population growth and ageing. Our findings in-
form policy makers of the EMR countries that
headache is a health care priority, and preventive
and management interventions must be imple-
mented to address the growing burden of headache
in this region. More studies are needed to provide
more accurate data on the prevalence and severity
of primary headache disorders in EMR as well as
more efficient preventive and management methods
to reduce the burden of headache.
Additional files
Additional file 1: (XLSX 26 kb)
Additional file 2: (XLSX 23 kb)
Abbreviations
DALY: Disability-adjusted life years; DW: Disability weight; EMR: Eastern
Mediterranean Region; GBD: Global Burden of Disease Study; IHME: Institute
for Health Metrics and Evaluation; LDI: Lag-distributed income;
MOH: Medication overuse headache; SDI: Socio-demographic Index;
SSA: Sub-Saharan Africa; TFR: Total fertility rate; TTH: Tension-type headache;
Table 4 YLD count, All-age YLD rates, and Age-standardised rates in 2016, and percentage change of YLD count, All-age YLD rates,
and Age-standardised rates between 1990 and 2016 for TTH in EMR countries












Somalia 7156 (4481-10831) 67.4 (58.5 to 77.6) 85 (54-128) -1.3 (-6.1 to 4.2) 0.89 1.32 0.27
Afghanistan 35909 (22613-53732) 201.6 (186.6 to 218.1) 135 (85-200) 1.5 (-3.1 to 6.5) 1.4 1.39 0.28
Djibouti 706 (447-1058) 76.4 (64 to 90) 84 (53-125) -3.2 (-8.5 to 3.1) 0.85 1.33 0.42
Yemen 31337 (19858-47513) 183.3 (165.5 to 205.2) 138 (88-207) 2.5 (-2.9 to 9.2) 1.39 1.4 0.45
Middle-income Countries
Palestine 5548 (3486-8251) 164.6 (150.6 to 180.8) 139 (88-207) 1 (-3.6 to 6) 1.4 1.41 0.45
Iraq 42924 (27365-64414) 139.6 (126.8 to 154.5) 138 (88-206) 1.7 (-3.1 to 7.1) 1.39 1.42 0.47
Sudan 47952 (30469-71699) 129.9 (117.1 to 144.8) 140 (88-209) 3 (-2.1 to 9) 1.39 1.41 0.52
Pakistan 197112 (122210-292966) 98.4 (86.4 to 112.1) 114 (71-168) -0.7 (-5.9 to 5.4) 1.13 1.28 0.52
Morocco 49517 (31448-73822) 73.3 (61.1 to 87.9) 142 (91-213) 3.3 (-2.3 to 9.4) 1.38 1.41 0.62
Syria 23274 (14638-34911) 82.9 (69.2 to 97.9) 142 (89-212) 3.5 (-2.3 to 9.9) 1.37 1.42 0.64
Egypt 121944 (77062-181851) 90.2 (79.4 to 102) 142 (91-211) 3 (-2.2 to 8.9) 1.36 1.42 0.65
Jordan 9934 (6276-14876) 191.3 (170.6 to 215.2) 142 (91-212) 3.7 (-1.6 to 9.6) 1.35 1.41 0.69
Tunisia 17148 (10721-25799) 73.1 (59.7 to 87.1) 144 (90-216) 3.3 (-2.3 to 9.4) 1.37 1.42 0.70
Iran 128660 (82720-188190) 104.2 (87.8 to 122.8) 152 (98-222) 4.1 (-1.8 to 11) 1.42 1.41 0.77
Libya 9053 (5661-13629) 84 (69.9 to 99.5) 144 (92-214) 4.4 (-0.9 to 10.8) 1.35 1.43 0.81
Lebanon 8862 (5586-13274) 160.8 (145.8 to 178.3) 144 (91-216) 2.8 (-2.3 to 8.7) 1.35 1.43 0.81
High-income Countries
Oman 6862 (4261-10363) 259.7 (224.5 to 298.3) 135 (85-201) 0.9 (-6.7 to 9.2) 1.27 1.42 0.72
Bahrain 2112 (1327-3201) 234.2 (212.4 to 259.2) 136 (87-205) 1.4 (-4.1 to 6.8) 1.29 1.42 0.74
United Arab Emirates 15103 (9215-23288) 542.9 (493.5 to 600.3) 132 (82-198) 0.5 (-5.2 to 6.8) 1.24 1.42 0.77
Qatar 3540 (2191-5423) 464 (423.6 to 505.7) 130 (82-194) 2.1 (-3.5 to 8.2) 1.22 1.45 0.79
Saudi Arabia 44858 (28544-65886) 160.2 (140.2 to 180) 137 (88-199) 5.3 (-0.3 to 10.5) 1.28 1.39 0.80
Kuwait 6281 (3929-9644) 138.3 (121.4 to 157.8) 141 (89-213) 2.6 (-2.9 to 8.9) 1.32 1.42 0.83
EMR and global
EMR 815789 (516411-1221998) 112.8a 134 (85-198) 2.5a 1.29 1.38 N/A
Global 7195122 (4614628-10499903) 53.2 (47.5 to 58.4) 96 (62-140) -0.2 (-2.5 to 1.9) 0.91 1.48 0.70
YLD years lived with disability, TTH tension-type headache, EMR eastern Mediterranean region
a Uncertainty interval is not available
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